Baker entities obtained 7.8% voting power over BeOne Medicines Ltd. shares
Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Felix J. Baker and Julian C. Baker each reported holding 115,457,154 (LP and GP) or 115,912,814 (Felix and Julian) shares, representing 7.8% voting power in the BeOne Medicines Ltd. class, in a filing dated September 14, 2026.
Key points
- Baker Bros.
- A checked box in the Rule 10b5‑1 field does not prove the absence of a trading plan, and a notice of intent to sell shares is only an intention and does not indicate an actual transaction at this time.
What happened
Baker Bros. Advisors LP and Baker Bros. Advisors (GP) LLC have sole voting and dispositive power over 115,457,154 shares, while Felix J. Baker and Julian C. Baker have it over 115,912,814 shares; each controls 7.8% of the BeOne Medicines Ltd. class.
Director and chair of the Scientific Advisory Board Wang Xiaodong, in an insider‑trade filing dated September 28, 2026, bought 31,028 shares at an average price of $36.9 and immediately sold them on the open market for $364.7853 per share; he also sold 403,364 derivative securities, retaining 806,715.
Officer Chan Lee filed a notice of intended sale reporting a planned disposition of 1,115 ADS (American Depositary Shares) with an approximate date of September 30, 2026; the shares were acquired on July 29, 2022 as RSUs, and the trading plan was approved on May 29, 2026.
Lee Chan Henry, senior vice president and general counsel, in an insider‑trade filing for September 30, 2026, sold 1,115 ADS at an average price of $375 under Rule 10b5‑1, leaving zero shares after the sale.
Value of shares sold, by insider
What this does not mean
A checked box in the Rule 10b5‑1 field does not prove the absence of a trading plan, and a notice of intent to sell shares is only an intention and does not indicate an actual transaction at this time.
Original sources
- SCHEDULE 13D/A filing, September 16, 2026
- 4 filing, September 16, 2026
- 4 filing, September 30, 2026
- 144 filing, September 30, 2026
- 4 filing, October 2, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow BeOne Medicines
A notification in your browser or on your phone when we publish about BeOne Medicines. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
